Production (Stage)
VYNE Therapeutics Inc.
VYNE
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 140.48% | -30.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 140.48% | -30.58% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 140.48% | -30.58% | |||
| SG&A Expenses | 3.31% | 6.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.88% | -2.71% | |||
| Operating Income | 27.98% | 2.45% | |||
| Income Before Tax | 28.37% | 1.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.39% | 1.18% | |||
| Earnings from Discontinued Operations | 0.00% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.37% | 1.11% | |||
| EBIT | 27.98% | 2.45% | |||
| EBITDA | 28.02% | -- | |||
| EPS Basic | 28.49% | 1.16% | |||
| Normalized Basic EPS | 28.49% | 1.23% | |||
| EPS Diluted | 28.49% | 1.16% | |||
| Normalized Diluted EPS | 28.49% | 1.23% | |||
| Average Basic Shares Outstanding | 0.18% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||